TR BioSurgical's Orthopedic Breakthrough for Multi-Billion Dollar Veterinary Market

A new orthopedic bioscaffold implant has been developed for musculoskeletal disorders in companion animals, including dogs, horses and cats. Using a simple procedure, the bioscaffold device is implanted into injured tissue and provides a structural matrix for local repair cells, such as stem cells or fibroblasts, to attach and heal tissue by physiological repair mechanisms. The implant has been evaluate up to 90 days with no diminishing effects observed.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Few would debate that veterinary medicine is long overdue for safer, more effective options for managing osteoarthritis. Many of the drugs used in veterinary medicine can have harmful side effects and achieve suboptimal clinical benefits. Our team has developed a cost effetive bioscaffold that has achieved optimal clinical outcomes in dogs that are poorly responsive to medical management.

Chandler, Ariz. (PRWEB) July 15, 2009

TR BioSurgical, LLC, announced highly encouraging results using a new medical device (bioscaffold) in canine patients with advanced osteoarthritis. Using a very simple procedure, the device is implanted in or near injured tissue and provides a structural matrix for existing repair cells, such as stem cells or fibroblasts, to infiltrate and heal tissue. TR BioSurgicals' veterinarians are highly encouraged by the implant's long term performance, currently evaluated beyond 90 days after a single implant procedure.

Osteoarthritis is the leading cause of disability in dogs and is estimated to affect twenty five percent of the dog population. It is estimated that owners spend over one billion dollars per year in the United States just for canine orthopedic related diseases.

Dr. Jeff Kellerman, VP of R&D at TR BioSurgical, further added, "Few would debate that veterinary medicine is long overdue for safer, more effective options for managing osteoarthritis. Many of the drugs used in veterinary medicine can have harmful side effects and achieve suboptimal clinical benefits. Our team has developed a cost effetive bioscaffold that has achieved optimal clinical outcomes in dogs that are poorly responsive to medical management."

About the Implant: The new bioscaffold implant contains no drugs, cells or growth factors. It serves as a structural scaffold for existing cells and provides an environment for physiological tissue repair. The implant is made from a proprietary, copolymerized collagen and is sterile, cost effective, and non- immunogenic. The implant has demonstrated impressive results in patients with chronic joint problems.

About TR BioSurgical, LLC: TR BioSurgical is a privately held veterinary company developing a range of biomaterials and devices for tissue repair and regenerative medicine. TR BioSurgical has specific interests in ophthalmology, dermatology, and orthopedics including cartilage repair. TR BioSurgical has one osteopromotive scaffold to market, TR Matrix™, for use in companion animals for bone repair. The company has a strong pipeline of advanced medical device technologies under development. Please visit http://www.trbio.com for more information.

###


Contact